×
Request Free Sample ×
Myasthenia Gravis Market Research Report – Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Myasthenia Gravis Market

ID: MRFR/HC/5800-CR
200 Pages
Rahul Gotadki
December 2024

Myasthenia Gravis Market Research Report: Size, Share, Trend Analysis By Disease Type (Acetylcholine Receptor Antibody Positive Myasthenia Gravis, Muscle-Specific Kinase Antibody Positive Myasthenia Gravis, Seronegative Myasthenia Gravis), By Treatment Type (Anticholinesterase Agents, Immunosuppressants, Intravenous Immunoglobulin, Plasmapheresis, Thymectomy), By Route of Administration (Oral, Intravenous, Subcutaneous), By End Users (Hospitals, Specialty Clinics, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Myasthenia Gravis Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Myasthenia Gravis Market Summary

As per MRFR analysis, the Myasthenia Gravis Market Size was estimated at 1395.16 USD Million in 2024. The Myasthenia Gravis industry is projected to grow from 1497.29 USD Million in 2025 to 3034.75 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 7.32% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Myasthenia Gravis market is poised for growth driven by innovative therapies and increasing awareness.

  • The emergence of novel therapeutics is reshaping treatment paradigms in the Myasthenia Gravis market.
  • North America remains the largest market, while Asia-Pacific is recognized as the fastest-growing region.
  • Anticholinesterase inhibitors dominate the market, whereas monoclonal antibodies are experiencing rapid growth.
  • The rising prevalence of Myasthenia Gravis and advancements in treatment options are key drivers of market expansion.

Market Size & Forecast

2024 Market Size 1395.16 (USD Million)
2035 Market Size 3034.75 (USD Million)
CAGR (2025 - 2035) 7.32%

Major Players

Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Pfizer (US), Merck & Co. (US), Amgen (US), Eisai (JP), AstraZeneca (GB)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Myasthenia Gravis Market Trends

The Myasthenia Gravis Market is currently experiencing notable developments driven by advancements in treatment options and increased awareness of the condition. As healthcare professionals and researchers delve deeper into the complexities of this neuromuscular disorder, innovative therapies are emerging, potentially enhancing patient outcomes. The growing understanding of Myasthenia Gravis, coupled with improved diagnostic techniques, appears to be fostering a more proactive approach to management and care. This shift may lead to a more tailored treatment landscape, addressing the unique needs of individuals affected by the disease. Moreover, the Myasthenia Gravis Market is likely to benefit from collaborative efforts among pharmaceutical companies, academic institutions, and healthcare providers. These partnerships may facilitate the development of novel therapies and enhance access to existing treatments. As the global population ages, the prevalence of autoimmune disorders, including Myasthenia Gravis, is expected to rise, further emphasizing the need for effective management strategies. The market's evolution suggests a promising future, with potential breakthroughs on the horizon that could significantly impact the lives of those living with this condition.


Emergence of Novel Therapeutics


The Myasthenia Gravis Market is witnessing a surge in the development of innovative treatment options. Researchers are exploring various therapeutic avenues, including monoclonal antibodies and gene therapies, which may offer more effective management of symptoms. This trend indicates a shift towards personalized medicine, where treatments are tailored to individual patient profiles, potentially improving overall efficacy.


Increased Awareness and Diagnosis


There is a growing recognition of Myasthenia Gravis among healthcare professionals and the general public. Enhanced awareness campaigns and educational initiatives are likely contributing to earlier diagnosis and intervention. This trend may lead to improved patient outcomes, as timely treatment can significantly mitigate the impact of the disease.


Collaborative Research Initiatives


The Myasthenia Gravis Market is benefiting from collaborative efforts among various stakeholders, including pharmaceutical companies, research institutions, and patient advocacy groups. These partnerships are fostering innovation and accelerating the development of new therapies. Such collaborations may enhance the overall understanding of the disease and lead to more effective treatment strategies.

Myasthenia Gravis Market Drivers

Increasing Prevalence of Myasthenia Gravis

The Global Myasthenia Gravis Market Industry is witnessing a notable increase in the prevalence of myasthenia gravis, a chronic autoimmune disorder characterized by weakness in the skeletal muscles. Current estimates suggest that the incidence rate is approximately 20 cases per 100,000 people, with a higher prevalence observed in women, particularly those aged 20 to 40. This rising incidence is likely to drive demand for innovative therapies and treatment options, contributing to the market's growth. As the population ages, the number of individuals affected by this condition is expected to rise, further emphasizing the need for effective management strategies within the Global Myasthenia Gravis Market Industry.

Market Segment Insights

By Treatment Type: Anticholinesterase Inhibitors (Largest) vs. Monoclonal Antibodies (Fastest-Growing)

Among the treatment types for Myasthenia Gravis, Anticholinesterase Inhibitors hold the largest market share, widely utilized for their effectiveness in alleviating symptoms by enhancing neuromuscular transmission. In contrast, Monoclonal Antibodies, while currently a smaller segment in terms of market share, are rapidly gaining traction due to their innovative mechanisms and targeted therapies. Their adoption is anticipated to increase as awareness and research into their benefits grow. The growth trends within the Myasthenia Gravis treatment segment are driven by advancements in drug development and a deeper understanding of the disease mechanisms. Immunosuppressants and Intravenous Immunoglobulin are expected to continue playing significant roles as cornerstones of treatment. The increasing prevalence of Myasthenia Gravis and rising investment in biopharmaceuticals are anticipated to propel both established and emerging treatment types forward, emphasizing the varying dynamics within this segment.

Anticholinesterase Inhibitors (Dominant) vs. Monoclonal Antibodies (Emerging)

Anticholinesterase Inhibitors, such as Pyridostigmine, remain the dominant force in the treatment of Myasthenia Gravis due to their long-standing efficacy in improving muscle strength and endurance for patients. This group of medications works by inhibiting the breakdown of acetylcholine, thereby enhancing neuromuscular transmission. On the other hand, Monoclonal Antibodies represent an emerging class of treatments that are gaining significance in the market. These therapies, which include agents like Eculizumab, offer targeted mechanisms to modulate the immune response more precisely. The rising adoption of such therapies indicates a shift toward personalized medicine in treating Myasthenia Gravis, potentially providing benefits for patients who do not respond adequately to traditional therapies.

By Disease Severity: Moderate (Largest) vs. Severe (Fastest-Growing)

The Myasthenia Gravis market exhibits a diverse distribution of disease severity, with the moderate segment commanding the largest share due to a higher prevalence of moderate cases diagnosed. This segment accounts for a substantial portion of the market, reflecting a significant need for targeted treatment options. Conversely, the severe and crisis segments are gaining prominence, indicating a shift as clinical awareness and interventions improve. The crisis segment, while smaller, shows rapid growth driven by rising recognition of its critical nature and necessitated healthcare interventions.

Disease Severity: Moderate (Dominant) vs. Severe (Emerging)

The moderate severity segment of Myasthenia Gravis stands out as the dominant category due to the considerable number of diagnosed patients who experience significant symptoms yet maintain a level of functional independence. These individuals often require ongoing treatment to manage symptoms, presenting a stable market for pharmaceutical therapies. In contrast, the severe category, characterized by debilitating symptoms and potential for crisis events, is emerging as a critical area of focus for healthcare providers. Rapid advancements in targeted therapies and a better understanding of the disease dynamics fuel interest and investment in this increasingly recognized segment.

By Patient Demographics: Age (Largest) vs. Gender (Fastest-Growing)

In the Myasthenia Gravis market, age demographics significantly influence the prevalence and severity of the disease. The majority of the patient population is over 50 years old, accounting for a substantial percentage of diagnosed cases. This age group is largely a result of the progressive nature of Myasthenia Gravis, which commonly develops after mid-life. Conversely, the younger demographic, particularly those aged 20 to 40, shows increasing diagnosis rates, indicating a growing recognition of the disease among younger patients. Gender demographics reveal important insights, as women, particularly in the age group of 30 to 50, are diagnosed more frequently than men. However, recent trends show that the incidence of Myasthenia Gravis among men is increasing, making it one of the fastest-growing segments in this market. This shift could be attributed to raised awareness and improved diagnostic capabilities, enabling better identification of cases among male patients who previously went undiagnosed.

Age Group: 50+ (Dominant) vs. Gender: Male (Emerging)

The 50+ age group is the dominant demographic in the Myasthenia Gravis market, as this cohort is most affected by the disease due to its progressive nature. Patients in this age bracket often experience more severe manifestations and complications, which influences their healthcare needs and treatment options. Meanwhile, the male demographic is emerging as a significant segment of the patient population. Increased recognition and diagnosis of Myasthenia Gravis in younger males can be linked to advocacy and awareness efforts that spotlight atypical symptoms. These men may have different treatment responses and challenges compared to their female counterparts, indicating the need for tailored therapeutic approaches.

By Administration Route: Oral (Largest) vs. Intravenous (Fastest-Growing)

In the Myasthenia Gravis Market, the Administration Route segment is diversified, with Oral treatments holding a significant share. Oral administration is favored due to its convenience and ease of use, making it a preferred choice for many patients. Meanwhile, Intravenous administration, although currently smaller in market share, is witnessing rapid adoption thanks to its effectiveness in treating acute cases, hence its designation as the fastest-growing route of administration in this segment. The growth trends within the Administration Route segment are influenced by the increasing prevalence of Myasthenia Gravis and the push towards personalized medicine. Physicians are leaning towards routes that provide rapid therapeutic effects, which elevates Intravenous methods. Additionally, the rising collaborations between pharmaceutical companies and healthcare providers to develop new treatment modalities bolsters the drive for both Oral and Intravenous administration routes.

Administration Route: Oral (Dominant) vs. Intravenous (Emerging)

Within the Administration Route segment of the Myasthenia Gravis Market, Oral administration stands out as the dominant choice, preferred for its ease and accessibility among patients. It typically involves less complicated healthcare management, which appeals to both healthcare professionals and patients. On the other hand, Intravenous administration has emerged as a key area of growth, particularly in acute Myasthenia Gravis cases requiring immediate treatment. The characteristics of Intravenous routes, such as faster onset of action, address critical patient needs, thus positioning it as an emerging alternative in treatment protocols. In summary, while Oral administration remains a staple for chronic management, Intravenous routes are carving out a niche for urgent care, driven by the need for effective management of severe symptoms.

By Healthcare Setting: Hospital (Largest) vs. Outpatient Clinic (Fastest-Growing)

In the Myasthenia Gravis market, the distribution of healthcare settings reflects varied preferences among patients and practitioners. Hospitals hold a significant market share, providing comprehensive care and advanced treatment options for severe cases of Myasthenia Gravis. Outpatient clinics, however, are rapidly gaining traction as patients increasingly seek flexible treatment options for ongoing management outside traditional hospital settings. The growth of these clinics points toward a shift in patient preferences toward more accessible and cost-effective solutions.

Hospital (Dominant) vs. Outpatient Clinic (Emerging)

Hospitals represent the dominant healthcare setting for managing Myasthenia Gravis due to their capacity for delivering complex and multi-disciplinary care. They are equipped with specialized medical teams and technologies necessary for diagnosing and managing the complications of the disease. On the other hand, outpatient clinics are emerging as an alternative for patients preferring routine follow-ups and therapies without hospital stays. These clinics offer convenience, improved patient engagement, and can serve as effective long-term management sites, especially for less severe cases where immediate hospital intervention is not necessary.

Get more detailed insights about Myasthenia Gravis Market
Request Free Sample

Regional Insights

North America : Market Leader in Myasthenia Gravis

North America is poised to maintain its leadership in the Myasthenia Gravis market, holding a significant market share of $700.0M in 2024. The region's growth is driven by increasing prevalence rates, advancements in treatment options, and supportive regulatory frameworks. The FDA's expedited approval processes for innovative therapies further catalyze market expansion, meeting the rising demand for effective treatments. The competitive landscape in North America is robust, featuring key players such as Roche, Bristol-Myers Squibb, and Pfizer. These companies are actively engaged in research and development, focusing on novel therapies and personalized medicine. The presence of established healthcare infrastructure and investment in clinical trials enhances the region's attractiveness for market players, ensuring continued growth and innovation in the Myasthenia Gravis sector.

Europe : Emerging Market with Growth Potential

Europe is witnessing a growing Myasthenia Gravis market, valued at $400.0M in 2024. The region benefits from increasing awareness of the disease, improved diagnostic capabilities, and a rise in healthcare expenditure. Regulatory bodies are also playing a crucial role in facilitating access to new treatments, which is expected to drive market growth in the coming years. Leading countries such as Germany, France, and the UK are at the forefront of this market, supported by a strong presence of pharmaceutical companies like Novartis and Sanofi. The competitive landscape is characterized by strategic collaborations and partnerships aimed at enhancing treatment options. As the market evolves, the focus on patient-centric approaches and innovative therapies will be key to capturing market share.

Asia-Pacific : Emerging Powerhouse in Healthcare

The Asia-Pacific region is emerging as a significant player in the Myasthenia Gravis market, with a market size of $250.0M in 2024. Factors such as increasing healthcare investments, rising awareness of neurological disorders, and a growing patient population are driving demand. Additionally, supportive government initiatives aimed at improving healthcare access are expected to further boost market growth in this region. Countries like Japan, China, and Australia are leading the charge, with a growing number of clinical trials and research activities. Key players such as Eisai and Amgen are actively involved in developing innovative therapies tailored to the needs of the region. The competitive landscape is evolving, with a focus on collaboration between local and international firms to enhance treatment availability and patient outcomes.

Middle East and Africa : Developing Market with Challenges

The Middle East and Africa (MEA) region is gradually developing its Myasthenia Gravis market, currently valued at $45.16M in 2024. The growth is hindered by challenges such as limited healthcare infrastructure and varying levels of disease awareness. However, increasing investments in healthcare and initiatives to improve access to treatments are expected to drive market growth in the coming years. Countries like South Africa and the UAE are leading the market, with efforts to enhance healthcare services and patient education. The presence of global players is also increasing, as companies seek to tap into this emerging market. Collaborative efforts between governments and private sectors are essential to address the challenges and improve treatment accessibility for patients in the region.

Myasthenia Gravis Market Regional Image

Key Players and Competitive Insights

The Myasthenia Gravis Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for innovative therapies. Key players such as Roche (CH), Bristol-Myers Squibb (US), and Novartis (CH) are actively shaping the market through strategic initiatives focused on research and development, partnerships, and regional expansion. Roche (CH) has positioned itself as a leader in the market by investing heavily in clinical trials aimed at developing novel therapies, while Bristol-Myers Squibb (US) emphasizes strategic collaborations to enhance its product pipeline. Novartis (CH) is also notable for its commitment to innovation, particularly in gene therapies, which could redefine treatment paradigms in the near future. The competitive structure of the Myasthenia Gravis Market appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. This trend is indicative of a broader strategy among key players to strengthen their market positions while responding to the unique needs of various regional markets. The collective influence of these companies is shaping a competitive environment that prioritizes innovation and responsiveness to patient needs. In November 2025, Roche (CH) announced the initiation of a pivotal Phase III clinical trial for its novel monoclonal antibody targeting Myasthenia Gravis. This strategic move underscores Roche's commitment to advancing treatment options and potentially capturing a larger market share. The trial's outcomes could significantly impact the company's positioning, especially if the therapy demonstrates superior efficacy compared to existing treatments. In October 2025, Bristol-Myers Squibb (US) entered into a strategic partnership with a biotechnology firm to co-develop a new immunotherapy for Myasthenia Gravis. This collaboration is expected to leverage both companies' strengths in research and development, potentially accelerating the timeline for bringing innovative therapies to market. Such partnerships are increasingly vital in a landscape where speed to market can determine competitive advantage. In September 2025, Novartis (CH) launched a new digital platform aimed at enhancing patient engagement and adherence to treatment regimens for Myasthenia Gravis. This initiative reflects a growing trend towards digitalization in healthcare, where technology is utilized to improve patient outcomes. By integrating digital tools into its strategy, Novartis is likely positioning itself as a forward-thinking leader in the market. As of December 2025, the Myasthenia Gravis Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming increasingly important, as companies recognize the need to pool resources and expertise to navigate the complexities of the market. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies approach market entry and product development, ultimately benefiting patients through improved treatment options.

Key Companies in the Myasthenia Gravis Market include

Industry Developments

  • Q4 2024: UCB receives FDA approval for ZILBRYSQ (zilucoplan) for generalized myasthenia gravis in adults UCB announced that the U.S. FDA approved ZILBRYSQ (zilucoplan), a once-daily subcutaneous peptide inhibitor, for the treatment of generalized myasthenia gravis in adult patients, marking a significant regulatory milestone for the company.
  • Q2 2024: Argenx receives European Commission approval for Vyvgart for generalized myasthenia gravis Argenx secured European Commission approval for its drug Vyvgart (efgartigimod alfa) for the treatment of generalized myasthenia gravis, expanding its market presence in Europe.
  • Q1 2024: Alexion, AstraZeneca Rare Disease, announces positive Phase 3 results for Ultomiris in myasthenia gravis Alexion, AstraZeneca Rare Disease, reported positive Phase 3 clinical trial results for Ultomiris (ravulizumab) in patients with generalized myasthenia gravis, paving the way for potential regulatory submissions.
  • Q2 2024: UCB partners with Roche to co-develop new monoclonal antibody for myasthenia gravis UCB and Roche announced a strategic partnership to co-develop a next-generation monoclonal antibody targeting refractory myasthenia gravis, aiming to address unmet clinical needs.
  • Q3 2024: Argenx raises $400 million in public offering to expand myasthenia gravis drug portfolio Argenx completed a $400 million public offering to support the expansion of its myasthenia gravis drug portfolio and fund ongoing clinical trials.
  • Q2 2025: Descartes-08 receives FDA Fast Track designation for myasthenia gravis Descartes-08, a novel RNA-engineered cell therapy, was granted Fast Track designation by the FDA for the treatment of generalized myasthenia gravis, accelerating its development timeline.
  • Q1 2025: AstraZeneca opens new manufacturing facility for myasthenia gravis biologics in the US AstraZeneca inaugurated a new state-of-the-art manufacturing facility in the United States dedicated to producing biologics for rare diseases, including myasthenia gravis.
  • Q2 2024: Immunovant announces $230 million Series C funding to advance anti-FcRn antibody for myasthenia gravis Immunovant raised $230 million in Series C funding to accelerate the development of its anti-FcRn antibody, IMVT-1402, for the treatment of myasthenia gravis.
  • Q3 2024: Janssen submits BLA to FDA for nipocalimab in generalized myasthenia gravis Janssen, a Johnson & Johnson company, submitted a Biologics License Application (BLA) to the FDA for nipocalimab, a monoclonal antibody for the treatment of generalized myasthenia gravis.
  • Q2 2025: Telitacicept receives conditional approval in China for myasthenia gravis Telitacicept, developed by RemeGen, received conditional approval from Chinese regulators for the treatment of myasthenia gravis, marking its first market entry.
  • Q1 2025: UCB appoints new Head of Rare Disease Division to lead myasthenia gravis strategy UCB announced the appointment of a new Head of Rare Disease Division to oversee its global strategy for myasthenia gravis and other rare autoimmune disorders.
  • Q4 2024: CRD-1 initiates Phase 2 trial for seronegative myasthenia gravis patients CRD-1, a novel therapeutic candidate, began Phase 2 clinical trials targeting seronegative myasthenia gravis patients, addressing a significant unmet need in the market.

Future Outlook

Myasthenia Gravis Market Future Outlook

The Myasthenia Gravis Market is projected to grow at a 7.32% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing awareness.

New opportunities lie in:

  • Development of targeted biologics for personalized treatment plans. Expansion of telehealth services for remote patient monitoring. Investment in AI-driven diagnostic tools for early detection.

By 2035, the Myasthenia Gravis Market is expected to achieve substantial growth and innovation.

Market Segmentation

Myasthenia Gravis Market Treatment Type Outlook

  • Anticholinesterase Inhibitors

  • Immunosuppressants

  • Monoclonal Antibodies

  • Plasmapheresis

  • Intravenous Immunoglobulin

Myasthenia Gravis Market Disease Severity Outlook

  • Mild

  • Moderate

  • Severe

  • Crisis

  • Remission

Myasthenia Gravis Market Healthcare Setting Outlook

  • Hospital

  • Outpatient Clinic

  • Home Healthcare

  • Long-term Care Facility

  • Specialized Treatment Center

Myasthenia Gravis Market Administration Route Outlook

  • Oral

  • Intravenous

  • Subcutaneous

  • Intramuscular

  • Topical

Myasthenia Gravis Market Patient Demographics Outlook

  • Age

  • Gender

  • Ethnicity

  • Socioeconomic Status

  • Geographic Distribution

Report Scope

MARKET SIZE 2024 1395.16(USD Million)
MARKET SIZE 2025 1497.29(USD Million)
MARKET SIZE 2035 3034.75(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.32% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Pfizer (US), Merck & Co. (US), Amgen (US), Eisai (JP), AstraZeneca (GB)
Segments Covered Treatment Type, Disease Severity, Patient Demographics, Administration Route, Healthcare Setting
Key Market Opportunities Advancements in targeted therapies and personalized medicine enhance treatment options in the Myasthenia Gravis Market.
Key Market Dynamics Rising demand for innovative therapies drives competitive dynamics in the Myasthenia Gravis market.
Countries Covered North America, Europe, APAC, South America, MEA

Market Highlights

Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch
Leave a Comment

FAQs

What is the projected growth of the Myasthenia Gravis market?

The Myasthenia Gravis market is the expected increase in total market value of 3.03 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Myasthenia Gravis market?

Myasthenia Gravis market size was valued at approximately 1.4 billion USD in 2024. This figure will reach 3.03 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Myasthenia Gravis market?

Myasthenia Gravis market is expected to grow at a CAGR of 7.32% between 2025 and 2035.

How much will the Myasthenia Gravis market be worth by 2035?

Myasthenia Gravis market is expected to be worth of 3.03 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Myasthenia Gravis market perform over the next 10 years?

Over the next 10 years the Myasthenia Gravis market is expected to shift from usd billion 1.4 to 3.03 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What is the total expected value of the Global Myasthenia Gravis Market in 2024?

The Global Myasthenia Gravis Market is expected to be valued at 2.11 USD Billion in 2024.

Which region holds the largest market share in the Global Myasthenia Gravis Market in 2024?

North America holds the largest market share with a value of 0.9 USD Billion in 2024.

What is the estimated market value for Europe in the Global Myasthenia Gravis Market by 2035?

The estimated market value for Europe is projected to be 1.4 USD Billion by 2035.

What market size is anticipated for Acetylcholine Receptor Antibody Positive Myasthenia Gravis in 2024?

The market size for Acetylcholine Receptor Antibody Positive Myasthenia Gravis is expected to be 0.87 USD Billion in 2024.

Who are the key players in the Global Myasthenia Gravis Market?

Key players include Pfizer, Merck & Co, Roche, Johnson & Johnson, and UCB among others.

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of neurological disorder registries, peer-reviewed neurology journals, clinical trial databases, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Drug Evaluation and Research, European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), National Institute of Neurological Disorders and Stroke (NINDS), Centers for Disease Control and Prevention (CDC) National Center for Chronic Disease Prevention and Health Promotion, National Institutes of Health (NIH) Neurological Institute, National Center for Biotechnology Information (NCBI/PubMed), ClinicalTrials.gov registry, World Health Organization (WHO) Neurological Disorders Program, Myasthenia Gravis Foundation of America (MGFA), Myasthenia Gravis Association (UK), World Muscle Society (WMS), American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), European Federation of Neurological Associations (EFNA), national health ministry reports from key markets, and IQVIA prescription data. These sources were used to collect epidemiology statistics, treatment paradigm shifts, regulatory approval data for monoclonal antibodies (eculizumab, efgartigimod, rozanolixizumab), clinical safety and efficacy studies, patient demographic trends, and competitive landscape analysis for acetylcholinesterase inhibitors, immunosuppressants, IVIG therapies, and emerging FcRn antagonists.

Primary Research

To gather both qualitative and quantitative information, the primary research process involved interviewing players from both the supply and demand sides. Members of the supply side included pharmaceutical companies with a focus on neurology, biotech companies working on autoimmune treatments, and companies making plasma-derived products. They also included vice presidents of clinical development, chiefs of regulatory affairs, and commercial directors. Neurologists, immunologists, clinical pharmacists, hospital formulary decision-makers, medical directors of neurology centers, and procurement leads from academic medical centers, community hospitals, and specialty infusion centers were among the demand-side sources. We confirmed drug pipeline timelines (Phase III to commercialization), analyzed treatment adoption patterns, priced and reimbursed novel biologics, and found patterns of switching between symptomatic and disease-modifying therapies. Primary research also validated market segmentation across antibody-positive and seronegative subtypes.

Primary Respondent Breakdown:

By Designation: C-level Primaries (28%), Director Level (42%), Others (30%)

By Region: North America (32%), Europe (29%), Asia-Pacific (34%), Rest of World (5%)

Market Size Estimation

Global market valuation was derived through revenue mapping, prescription volume analysis, and procedure data for thymectomy interventions. The methodology included:

Identification of 35+ key manufacturers and developers across North America, Europe, Asia-Pacific, and Latin America, including players in monoclonal antibodies, biosimilars, and generic immunosuppressants

Product mapping across acetylcholinesterase inhibitors (pyridostigmine), chronic immunosuppressants (azathioprine, mycophenolate, tacrolimus), rapid immunotherapies (IVIG, plasmapheresis), and biologics (complement inhibitors, FcRn antagonists, anti-CD20 therapies)

Analysis of reported and modeled annual revenues specific to myasthenia gravis portfolios, including antibody-positive and seronegative patient segment allocations

Coverage of manufacturers representing 75-80% of global market share in 2024 (generics and originators)

Extrapolation using bottom-up (disease prevalence × diagnosis rate × treatment penetration × annual therapy cost by country) and top-down (manufacturer revenue validation across neurology franchises) approaches to derive segment-specific valuations for symptomatic, maintenance, and rescue therapy categories

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓